and extrapolated it in Mikolajczyk & Stanford's graph (2007) to find out what proportions result from anovulatory or post-fertilisation effects.

Results The pregnancy rate was 1.0% taking the pill 1–4 days after intercourse (66 pregnancies in 6,564 women), and 5.2% if it was taken on the fifth day (12 in 230 women). It shows a minimum reduction in the probability of pregnancy of 80.7% (IC95 64.9–89.4%).

In a conservative approach, administering the pill 24 h after intercourse, we obtained an anovulatory effect of 50%. However, taking into account epidemiological data showing lack of effect on pregnancy rates at a population level, we could assume an actual decrease that could be in the lower top of the confidence interval (64.9%). Extrapolating this effect, we obtained a contribution of 65% for the anovulatory mechanism.

Conclusions As an alternative pre-fertilisation effect is unlikely, we postulate at least 35% post-fertilisation effects for post-coital levonorgestrel. This is statistically compatible with the previous contradictory Nøe et al's data, as they observed only 35 women.

No conflict of interest.

B Aparicio García, J Alonso Herreros, JJ Franco Miguel. Hospital Universitario Reina Sofia, Pharmacy, Murcia, Spain

Background Alpha tumour necrosis factor inhibitors (TNF inhibitors) represent an important advance in immune-mediated inflammatory diseases. The first three drugs marketed and most used nowadays within this family are: infliximab, etanercept, and adalimumab.

There is no apparent superiority between any of these drugs and it is known they often lose their efficacy over time. Therefore, it could be of interest to find out if any of them (under usual clinical conditions) has a longer period of time without loss of efficacy.

Purpose To compare the different treatments with TNF inhibitors, in order to find out which has the longest average duration (in days) before loss of treatment response finally requires a change in the treatment.

Materials and Methods All patients who began the treatment with TNF inhibitors between March 2007 and March 2012 and who had a change in treatment were analysed retrospectively with pharmacotherapy management software.

Patients who had stopped the treatment after presenting immediate adverse reactions in the first administration were excluded. The mean durations of treatment were compared using the Student’s t-test for unpaired data.

Results In total 309 patients were analysed. The three TNF inhibitor drugs most used were etanercept (Average duration 574.47 ± 461.51, N = 125), infliximab (Average duration 470.82 ± 469.64, N = 95) and adalimumab (Average duration 454.92 ± 378.89, N = 95). We found a significant difference between etanercept versus adalimumab (p-value = 0.0412), but not in the case of etanercept versus infliximab (p-value = 0.0997).

These results are coincident with Dr. Hetland’s study in 8074 patients (1). They also agree with the study presented by J A Markenson in 2418 patients (2). However our study results do not resemble those of G. Lapadula’s study (3).

Conclusions The average duration of treatment before requiring a change of drug is higher with etanercept than infliximab and adalimumab, but only is statistically significant with adalimumab. These results should be considered in the design of TNF inhibitor prescribing guidelines.

No conflict of interest.